Why Does Europe Do So Poorly? Some Inadequate Explanations

William Bains

Chapter 4 in Venture Capital and the European Biotechnology Industry, 2009, pp 42-54 from Palgrave Macmillan

Abstract: Abstract Thus the flower of biotechnology is a small weed in Europe compared to the giant redwood of the US. Why should this happen? Before delving into what I think is the main reason — the business practices of the VC groups that control the industry — it is worthwhile discussing the ‘reasons’ that are usually given, and showing why they are at most a minor cause of the relative lack of growth and frequent commercial and financial failure of the European industry. In this section I will explicitly leave out financial reasons such as the structure of the capital markets — we will deal with this in Chapter 6.

Keywords: Venture Capital; Biotechnology Company; Biotech Company; Deal Flow; Small Weed (search for similar items in EconPapers)
Date: 2009
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-0-230-22726-2_4

Ordering information: This item can be ordered from
http://www.palgrave.com/9780230227262

DOI: 10.1057/9780230227262_4

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().